InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders

Zydus receives China's NMPA approval for Venlafaxine ER capsules, 75 mg and 150 mg

Glenmark secures China approval for Ryaltris

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline

Henkel launches Packaging RecycLab in China

This integrated center combines development, testing, evaluation, and industry-academia-research collaboration

Bayer launches biotech innovation platform in China

Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis

Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China

Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)

Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China

SUP will obtain regulatory approvals for selling Tiotropium DPI in China

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion